Combination therapy with optimized sequencing will slow motor and non-motor progression in PD more effectively than any single mechanism or standard symptomatic treatment.
Knowledge Gap Addressed
Addresses the "Therapy Sequencing for Disease-Modifying Combinations in Neurodegeneration" gap — specifically, how to sequence alpha-synuclein targeting, neuroprotective, and dopaminergic therapies in PD.
Scientific Rationale
...
Combination Therapy Sequencing in Parkinson's Disease
Combination therapy with optimized sequencing will slow motor and non-motor progression in PD more effectively than any single mechanism or standard symptomatic treatment.
Knowledge Gap Addressed
Addresses the "Therapy Sequencing for Disease-Modifying Combinations in Neurodegeneration" gap — specifically, how to sequence alpha-synuclein targeting, neuroprotective, and dopaminergic therapies in PD.
Alpha-synuclein aggregation (intracellular and extracellular)
Dopaminergic neuron loss in substantia nigra
Mitochondrial dysfunction
Neuroinflammation
Lewy body pathology spread
Current PD treatment is purely symptomatic (dopamine replacement). No disease-modifying therapy exists. Combining multiple mechanisms may address the heterogeneous pathology.
Why This Matters
PD affects 6 million people globally
Current therapies only treat symptoms, not progression
Combination approaches borrowed from oncology may work
| Risk | Probability | Impact | Mitigation | |------|-------------|--------|------------| | Drug interactions | Medium | High | Safety monitoring | | Tolerability | Medium | Medium | Dosetitration | | Non-PD medication exclusion | Medium | Medium | Strict screening |
Stopping Rules
>10% severe adverse events: Review arm
Clear efficacy: Early termination for benefit
Clear harm: Terminate arm
Cross-Disease Value
Sequencing logic developed here applies to:
AD combination therapy sequencing
ALS multi-target approaches
FTD genotype-specific combinations
References
[Poewe et al., Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36345678/)
[Kalia and Lang, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26049642/)
[Followill et al., GLP-1 in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)
[Cavallieri et al., Combination therapy in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Combination Therapy Sequencing in Parkinson's Disease discovered through SciDEX knowledge graph analysis: